Effect of Pemafibrate on the Lipid Profile, Liver Function, and Liver Fibrosis Among Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
Gastroenterology Research · 2024-08 · 17 (4) · 159-174
DOI: 10.14740/gr1750 ↗At a glance
Journal article in Gastroenterology Research, 2024-08. Written by Mona Hassan and 18 co-authors. Institution: Gastroenterology and Hepatology Department, The University of Toledo, Toledo, OH, USA. Cited 11 times so far (Crossref). The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are prevalent conditions linked to obesity and metabolic disturbances, with potential complications such as cirrhosis and cardiovascular risks. This systematic review and meta-analysis aimed to evaluate the efficacy of pemafibrate, a drug targeting fat and sugar metabolism genes, in treating patients with MASLD/MASH.
Methods
Databases such as MEDLINE, Web of Science, Cochrane Library, and Scopus were searched until September 2023 to identify relevant studies. Selected studies underwent a thorough quality assessment using tools like Risk of Bias 2 tool (ROB-2) and the National Institutes of Health (NIH) Quality Assessment Tools. Comprehensive meta-analysis software was used for statistical evaluations, with a focus on lipid profiles, liver function tests, and fibrosis measurements.
Results
A total of 13 studies were included; 10 of them were included in the quantitative analysis. Our findings showed that pemafibrate significantly decreased low-density lipoprotein cholesterol (LDL-C) (effect size (ES) = -9.61 mg/dL, 95% confidence interval (CI): -14.15 to -5.08), increased high-density lipoprotein cholesterol (HDL-C) (ES = 3.15 mg/dL, 95% CI: 1.53 to 4.78), and reduced triglycerides (TG) (ES = -85.98 mg/dL, 95% CI: -96.61 to -75.36). Additionally, pemafibrate showed a marked reduction in liver enzyme levels, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyl transpeptidase (GGT), and alkaline phosphatase (ALP), with significant effect sizes and P values. For liver stiffness outcomes, pemafibrate decreased AST to platelet ratio index (APRI) (ES = -0.180, 95% CI: -0.221 to -0.138).
Conclusions
Pemafibrate, with its enhanced efficacy and safety profile, presents as a pivotal agent in MASLD/MASH treatment. Its lipid-regulating properties, coupled with its beneficial effects on liver inflammation markers, position it as a potentially invaluable therapeutic option.
Subjects
Author keywords
Authors and institutions
- Gastroenterology and Hepatology Department, The University of Toledo, Toledo, OH, USA.
- Internal Medicine Department, Jamaica Hospital Medicine Center, Queens, NY, USA.
- University of Toledo College of Medicine and Life Science, Toledo, OH, USA.
- Internal Medicine Department, Cleveland Clinic, Cleveland, OH, USA.
- Internal Medicine Department, College of Medicine, University of Baghdad, Baghdad, Iraq.
- Department of Health and Human Services, University of Michigan, Dearborn, MI, USA.
Cite
APA
Hassan, M., Al-Obaidi, H., Karrick, M., Merza, N., Nawras, Y., Saab, O., Al-Obaidi, A. D., Merza, F., Hashim, H. T., Al Zubaidi, K., Al-Sabbagh, D., Matbachi, R., Noori, Z., Amatul-Raheem, H., Mansur, S., Al Najafi, O., Algodi, M., Al Hamdany, T., & Kobeissy, A. (2024). Effect of Pemafibrate on the Lipid Profile, Liver Function, and Liver Fibrosis Among Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. Gastroenterology Research, 17(4), 159-174. https://doi.org/10.14740/gr1750
Vancouver
Hassan M, Al-Obaidi H, Karrick M, Merza N, Nawras Y, Saab O, et al. Effect of Pemafibrate on the Lipid Profile, Liver Function, and Liver Fibrosis Among Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. Gastroenterology Research. 2024;17(4):159-174. doi:10.14740/gr1750
BibTeX
@article{Hassan2024,
author = {Hassan, Mona and Al-Obaidi, Hasan and Karrick, Megan and Merza, Nooraldin and Nawras, Yusuf and Saab, Omar and Al-Obaidi, Ahmed Dheyaa and Merza, Fatima and Hashim, Hashim Talib and Al Zubaidi, Khalid and Al-Sabbagh, Daniah and Matbachi, Rand and Noori, Zainab and Amatul-Raheem, Hajra and Mansur, Sarmad and Al Najafi, Omer and Algodi, Marwah and Al Hamdany, Tamarah and Kobeissy, Abdallah},
title = {Effect of Pemafibrate on the Lipid Profile, Liver Function, and Liver Fibrosis Among Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease},
journal = {Gastroenterology Research},
year = {2024},
volume = {17},
number = {4},
pages = {159--174},
doi = {10.14740/gr1750}
}
EUVIMED